Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 2/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.37 |
| ▸ | NOS2 | P35228 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 7/20 | 0.36 |
| ▸ | HTR2A | P28223 | 4/20 | 0.36 |
| ▸ | HTR2B | P41595 | 4/20 | 0.36 |
| ▸ | CASP3 | P42574 | 1/20 | 0.34 |
| ▸ | ATR | Q13535 | 1/20 | 0.33 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
| ▸ | ACACA | Q13085 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6069866 | 0.87 | FPR2 (0.39) | FPR2SCN9AHTR2CHTR2AHTR2B | |
| SCHEMBL27993761 | 0.85 | HTR2A (0.38) | HTR2CHTR2AHTR2BATRATRIP | |
| SCHEMBL6069516 | 0.84 | FPR2 (0.38) | FPR2SCN9ACASP3ATRATRIP | |
| SCHEMBL3300676 | 0.84 | HTR2C (0.34) | FPR2SCN9AHTR2CHTR2AHTR2B | |
| SCHEMBL3298854 | 0.84 | HTR2C (0.34) | FPR2SCN9AHTR2CHTR2AHTR2B | |
| SCHEMBL5637366 | 0.76 | KDM4E (0.46) | HTR2CACACBACACA | |
| SCHEMBL15415761 | 0.75 | GPR119 (0.34) | FPR2SCN9ACASP3ATRATRIP | |
| SCHEMBL27561229 | 0.74 | SLC6A2 (0.44) | HTR2CHTR2AHTR2B | |
| SCHEMBL6992310 | 0.72 | HTR2C (0.39) | HTR2CHTR2AHTR2B | |
| SCHEMBL7372558 | 0.72 | MAPT (0.43) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6991902-B2 | Nucleobase heterocyclic combinatorialization | ISIS PHARMACEUTICALS, INC. (US) | 2006-01-31 | — | — | US | disclosed |
| US-6893815-B1 | Nucleobase heterocyclic combinatorialization | ISIS PHARMACEUTICALS, INC. (US) | 2005-05-17 | — | — | US | disclosed |
| US-20030003505-A1 | Nucleobase heterocyclic combinatorialization | ISIS PHARMACEUTICALS, INC. | 2003-01-02 | — | — | US | disclosed |
| US-20020009748-A1 | NUCLEOBASE HETEROCYCLIC COMBINATORIALIZATION | ISIS PHARMACEUTICALS, INC. | 2002-01-24 | — | — | US | disclosed |
| WO-1999000669-A1 | NUCLEOBASE HETEROCYCLIC COMBINATORIALIZATION | ISIS PHARMACEUTICALS, INC. (US) | 1999-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020009748-A1 | NUCLEOBASE HETEROCYCLIC COMBINATORIALIZATION | PNP, ATIC, DPYD | FPR2 1148/4885SCN9A 3577/4885NOS2 2981/4885 |
| US-20030003505-A1 | Nucleobase heterocyclic combinatorialization | PNP, ATIC, DPYD | FPR2 1148/4885SCN9A 3577/4885NOS2 2981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.